Hotez Peter J, Nuzhath Tasmiah, Callaghan Timothy, Colwell Brian
Texas Children's Hospital Center for Vaccine Development and Center for Medical Ethics and Health Policy, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Hagler Institute for Advanced Study at Texas A&M University, College Station, TX, USA; Scowcroft Institute of International Affairs, Bush School of Policy and Government, Texas A&M University, College Station, TX, USA; Department of Biology, Baylor University, Waco, TX, USA; James A Baker III Institute of Public Policy, Rice University Houston, Texas, USA.
Department of Health Promotion and Community Health Sciences, Texas A&M School of Public Health, College Station, TX, USA.
Microbes Infect. 2021 May-Jun;23(4-5):104811. doi: 10.1016/j.micinf.2021.104811. Epub 2021 Mar 17.
In the coming months, most American adults will have the opportunity to receive at least one of up to five different COVID-19 vaccines produced by Operation Warp Speed and released through emergency use authorization by the U.S. Food and Drug Administration (FDA). A similar group of vaccines will also be released in Europe by the European Medicines Agency (EMA) and in the United Kingdom by the Medicines & Healthcare products Regulatory Agency (MHRA). Those living outside of North America and Europe may not have access to those particular vaccines, but they will benefit from receiving vaccines produced in Brazil, China, India, or Russia. These vaccines and some of their major features based on clinical trials and testing are listed in Table 1 [1-25]. As vaccine scientists and policy experts working in the area of coronavirus disease 2019 (COVID-19), we are frequently asked about potential choices regarding the available vaccines, both in the U.S. and globally. Provided here is a summary and informal decision-making tool kit for considering the different vaccine options at this time.
在接下来的几个月里，大多数美国成年人将有机会接种由“曲速行动”（Operation Warp Speed）研发并经美国食品药品监督管理局（FDA）紧急使用授权的多达五种不同的新冠疫苗中的至少一种。欧洲药品管理局（EMA）也将在欧洲发布类似的一组疫苗，英国药品和保健品监管局（MHRA）将在英国发布。北美和欧洲以外地区的人们可能无法获得这些特定疫苗，但他们将受益于接种巴西、中国、印度或俄罗斯生产的疫苗。表1[1 - 25]列出了这些疫苗及其基于临床试验和测试的一些主要特征。作为从事2019冠状病毒病（COVID - 19）领域工作的疫苗科学家和政策专家，我们经常被问及在美国和全球范围内关于现有疫苗的潜在选择问题。以下是一个总结以及此时考虑不同疫苗选项的非正式决策工具包。
